Scinopharm TaiwanTPE:1789 +0.73%76 Gross Margin % is 33.04% as of Dec. 2025, which is 21% below its 10-year median of 41.70. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.10 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 936 Drug Manufacturers companies, Scinopharm Taiwan ranks worse than 74.57% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Scinopharm Taiwan had a gross margin of 33.04% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Scinopharm Taiwan Gross Margin % Related Terms
Scinopharm Taiwan Gross Margin % Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Scinopharm Taiwan (TPE:1789) has a Gross Margin % of 33.04% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Scinopharm Taiwan and its competitors. This is 21% below median its historical median of 41.70. Over the past decade, Scinopharm Taiwan's Gross Margin % has ranged from 34.66 to 46.36. According to the industry distribution chart, Scinopharm Taiwan ranks #698 out of 936 companies in the Drug Manufacturers industry, placing it in the top 74.6%.
Is Scinopharm Taiwan's Gross Margin % too high?
Scinopharm Taiwan's current Gross Margin % of 33.04% is 21% below median its 10-year median of 41.70. Over the past 10 years, this metric has ranged from a low of 34.66 to a high of 46.36. The Drug Manufacturers industry median Gross Margin % is 48.50. Scinopharm Taiwan's value of 33.04% is 31.9% below this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #698 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #698 out of 936 companies for Gross Margin %. This places Scinopharm Taiwan in the lower half of its industry. The industry median Gross Margin % is 48.50. Scinopharm Taiwan's value of 33.04% is 31.9% below this benchmark. Historically, Scinopharm Taiwan's own Gross Margin % has ranged from 34.66 to 46.36 over the past decade. While the company's 10-year median is 41.70 vs. the industry median of 48.50, Scinopharm Taiwan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current Gross Margin % of 33.04% is 31.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current Gross Margin % is 33.04%, which is 21% below median its own 10-year median of 41.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.10, compared to a current price of NT$20.65 — trading 23.8% below its estimated fair value. The current Gross Margin % is 33.04%, which is 21% below median its 10-year median of 41.70 and 31.9% below the Drug Manufacturers industry median of 48.50. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Gross Margin % is 33.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.65 is trading 23.8% below its estimated GF Value™ of NT$27.10.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Gross Margin %: 33.04% (21% below median its 10-year median of 41.70)
GF Value™: NT$27.10 vs. price of NT$20.65 (23.8% below fair value)
Industry Position: 31.9% below the Drug Manufacturers median (#698 of 936)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score
Get the complete analysis for TPE:1789
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
